The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease.
作者信息
Kamal Natasha, Marciano Beatriz, Curtin Bryan, Strongin Anna, DeRavin Suk See, Bousvaros Athos, Koh Christopher, Malech Harry L, Holland Steven M, Zerbe Christa, Heller Theo
机构信息
Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
出版信息
Gastroenterol Rep (Oxf). 2020 Mar 10;8(5):404-406. doi: 10.1093/gastro/goaa005. eCollection 2020 Oct.
Abstract
摘要
相似文献
1
The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease.维多珠单抗在慢性肉芽肿病相关炎症性肠病中的反应。
Gastroenterol Rep (Oxf). 2020 Mar 10;8(5):404-406. doi: 10.1093/gastro/goaa005. eCollection 2020 Oct.
2
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.维得利珠单抗与炎症性肠病患者固有免疫而非适应性免疫的改变相关。
Gut. 2019 Jan;68(1):25-39. doi: 10.1136/gutjnl-2018-316023. Epub 2018 May 5.
3
Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).维多珠单抗治疗炎症性肠病的长期疗效：一项基于瑞典国家炎症性肠病质量登记处（SWIBREG）的全国性研究。
Scand J Gastroenterol. 2017 Jun-Jul;52(6-7):722-729. doi: 10.1080/00365521.2017.1304987. Epub 2017 Mar 31.
4
Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study.定量对比增强超声监测维多珠单抗治疗炎症性肠病患者：一项初步研究。
Acta Radiol. 2018 Oct;59(10):1149-1156. doi: 10.1177/0284185117752032. Epub 2018 Jan 18.
5
Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.炎症性肠病患者使用“肠道特异性”维多珠单抗后的全身趋化因子水平——一项初步研究
Int J Mol Sci. 2017 Aug 22;18(8):1827. doi: 10.3390/ijms18081827.
6
Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.小儿炎症性肠病中维得利珠单抗的应用：来自 ESPGHAN 小儿炎症性肠病波尔图小组的回顾性多中心经验。
J Crohns Colitis. 2017 Oct 1;11(10):1230-1237. doi: 10.1093/ecco-jcc/jjx082.
7
Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease.维多利珠单抗在炎症性肠病围手术期的应用。
Curr Drug Targets. 2019;20(13):1317-1322. doi: 10.2174/1389450120666190325130142.
8
A product review of vedolizumab in inflammatory bowel disease.维得利珠单抗治疗炎症性肠病的产品评价。
Hum Vaccin Immunother. 2019;15(10):2482-2490. doi: 10.1080/21645515.2019.1591139. Epub 2019 May 7.
9
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. vedolizumab 水平、抗药物抗体和 α4β7 占有率与炎症性肠病患者反应的相关性。
Clin Gastroenterol Hepatol. 2018 May;16(5):697-705.e7. doi: 10.1016/j.cgh.2017.11.050. Epub 2017 Dec 7.
10
Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.维多珠单抗：减少炎症性肠病病理炎症的潜在作用机制
Front Cell Dev Biol. 2021 Feb 3;9:612830. doi: 10.3389/fcell.2021.612830. eCollection 2021.
引用本文的文献
1
Functional neutrophil disorders: Chronic granulomatous disease and beyond.功能异常的中性粒细胞疾病：慢性肉芽肿病及其他。
Immunol Rev. 2024 Mar;322(1):71-80. doi: 10.1111/imr.13308. Epub 2024 Mar 1.
2
Inflammatory Complications in Chronic Granulomatous Disease.慢性肉芽肿病中的炎症并发症
J Clin Med. 2024 Feb 15;13(4):1092. doi: 10.3390/jcm13041092.
3
Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.慢性肉芽肿病患者的肠道微生物组和代谢组特征。
J Allergy Clin Immunol. 2023 Dec;152(6):1619-1633.e11. doi: 10.1016/j.jaci.2023.07.022. Epub 2023 Sep 1.
4
Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases.单基因及极早发型炎症性肠病的药物治疗
Pharmaceutics. 2023 Mar 17;15(3):969. doi: 10.3390/pharmaceutics15030969.
5
Understanding inborn errors of immunity: A lens into the pathophysiology of monogenic inflammatory bowel disease.理解先天性免疫缺陷：单基因炎症性肠病病理生理学的一个视角。
Front Immunol. 2022 Sep 29;13:1026511. doi: 10.3389/fimmu.2022.1026511. eCollection 2022.
6
Linking Genetic Diagnosis to Therapeutic Approach in Very Early Onset Inflammatory Bowel Disease: Pharmacologic Considerations.将遗传诊断与极早发性炎症性肠病的治疗方法联系起来：药理学考虑。
Paediatr Drugs. 2022 May;24(3):207-216. doi: 10.1007/s40272-022-00503-4. Epub 2022 Apr 25.
7
Chronic Granulomatous Disease With Inflammatory Bowel Disease: Clinical Presentation, Treatment, and Outcomes From the USIDNET Registry.慢性肉芽肿病合并炎症性肠病：来自 USIDNET 注册研究的临床特征、治疗和结局。
J Allergy Clin Immunol Pract. 2022 May;10(5):1325-1333.e5. doi: 10.1016/j.jaip.2021.12.035. Epub 2022 Jan 14.
8
Lymphadenitis Following Infliximab Therapy for Inflammatory Bowel Disease in a Patient With Chronic Granulomatous Disease: Case Report and Literature Review.英夫利昔单抗治疗慢性肉芽肿病患者炎性肠病后发生的淋巴结炎：病例报告及文献综述
Front Pediatr. 2021 Oct 25;9:707369. doi: 10.3389/fped.2021.707369. eCollection 2021.
本文引用的文献
1
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis.在克罗恩病或溃疡性结肠炎患者中，Vedolizumab 失去应答和增加剂量恢复应答的能力：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2019 Apr;17(5):838-846.e2. doi: 10.1016/j.cgh.2018.06.026. Epub 2018 Jun 20.
2
Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.早期 vedolizumab 谷浓度可预测炎症性肠病的黏膜愈合：一项多中心前瞻性观察研究。
Aliment Pharmacol Ther. 2018 Apr;47(7):906-912. doi: 10.1111/apt.14548. Epub 2018 Jan 31.
3
Treatment of chronic granulomatous disease-associated fistulising colitis with vedolizumab.用维多珠单抗治疗慢性肉芽肿病相关的瘘管性结肠炎。
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1748-1749. doi: 10.1016/j.jaip.2017.07.035. Epub 2017 Sep 14.
4
Gastrointestinal Features of Chronic Granulomatous Disease Found During Endoscopy.内镜检查中发现的慢性肉芽肿病的胃肠道特征
Clin Gastroenterol Hepatol. 2016 Mar;14(3):395-402.e5. doi: 10.1016/j.cgh.2015.10.030. Epub 2015 Nov 9.
5
Treatment With Anakinra, a Recombinant IL-1 Receptor Antagonist, Unlikely to Induce Lasting Remission in Patients With CGD Colitis.使用重组白细胞介素-1受体拮抗剂阿那白滞素治疗慢性肉芽肿病（CGD）结肠炎患者不太可能诱导持久缓解。
Am J Gastroenterol. 2015 Jun;110(6):938-9. doi: 10.1038/ajg.2015.135.
6
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.英夫利昔单抗诱导治疗对肿瘤坏死因子拮抗剂治疗失败的克罗恩病患者的影响。
Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.
7
Vedolizumab as induction and maintenance therapy for Crohn's disease.维得利珠单抗作为克罗恩病的诱导缓解和维持治疗药物。
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
8
Vedolizumab as induction and maintenance therapy for ulcerative colitis.维得利珠单抗用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.
9
Residual NADPH oxidase and survival in chronic granulomatous disease.慢性肉芽肿病中残余烟酰胺腺嘌呤二核苷酸磷酸氧化酶与生存。
N Engl J Med. 2010 Dec 30;363(27):2600-10. doi: 10.1056/NEJMoa1007097.
10
Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.肿瘤坏死因子-α 阻断在慢性肉芽肿病相关性结肠炎中的并发症。
Clin Infect Dis. 2010 Dec 15;51(12):1429-34. doi: 10.1086/657308. Epub 2010 Nov 8.
Zotero 插件